Tides Medical

Tides Medical

Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $12.5M

Overview

Tides Medical is a private, commercial-stage company specializing in human amniotic tissue-based regenerative products for chronic wounds and surgical procedures. Its vertically integrated business encompasses tissue acquisition via its Louisiana Organization for Transplant (LOFT), aseptic processing and terminal sterilization in its AATB-accredited tissue bank, and a nationwide distribution network supported by a dedicated sales and reimbursement service team. The company's value proposition centers on providing high-quality, easy-to-use grafts coupled with exceptional customer support to remove administrative barriers for physicians, thereby improving patient access to advanced treatment options. Tides appears to be revenue-generating, serving a national market from its headquarters in Lafayette, Louisiana.

Wound CareSurgical Procedures

Technology Platform

Proprietary aseptic processing, terminal radiation sterilization, and preservation of human amniotic membrane for room-temperature stable biological grafts.

Funding History

2
Total raised:$12.5M
Series A$10M
Seed$2.5M

Opportunities

The growing global advanced wound care market, driven by diabetes and aging demographics, presents a significant expansion opportunity.
Tides' unique service-led model addressing reimbursement complexity is a powerful differentiator to capture market share from product-only competitors.
Room-temperature stable products offer a logistical advantage for outpatient settings, a rapidly growing care delivery segment.

Risk Factors

The company faces regulatory risk from the stringent FDA/AATB oversight of tissue products and reimbursement risk from volatile insurance coverage policies.
Supply chain is reliant on a consistent supply of donated placental tissue, introducing ethical and operational vulnerabilities.
The market is highly competitive with numerous established players, creating pricing and differentiation pressures.

Competitive Landscape

Tides competes in the crowded amniotic tissue and regenerative medicine market against larger public companies (e.g., Organogenesis with its NuShield/BioClaim products, MiMedx) and numerous private firms. Its primary competitive differentiation is not just the product, but its integrated service model focusing on reimbursement support. Competitors may have broader product portfolios or greater financial resources for R&D and marketing.